The plasticity of melanoma cells and associated clinical implications

From Melanocytes to Melanoma: The Progression to Malignancy

Volumn , Issue , 2006, Pages 533-550

  Hendrix, Mary J C ^a   Seftor, Elisabeth A ^a   Hess, Angela R ^a   Seftor, Richard E B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

angiogenesis; Melanoma; plasticity; vasculogenic mimicry

Indexed keywords

EID: 84891425773     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-994-3_30     Document Type: Chapter

References (107)

1. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-540.
2. Seftor EA, Seftor, Meltzer PS, et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastas 2002;19:233-246.
3. Seftor EA, Meltzer PS, Schatteman GC, et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 2002;44:17-27.
4. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-674.
5. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
6. Tomanek RJ, ed. Assembly of the Vasculature and Its Regulation. Birkhauser, Boston, MA: 2002.
7. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. New Eng J Med 1995;333:1757-1763.
8. Rak J, Kerbel RS. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metastas Rev 1996;15:231-236.
9. Kumar R, Fidler IJ. Angiogenic molecules and cancer metastasis. In Vivo 1998;12:27-34.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
11. Gullino PM. Angiogenesis and oncogenesis. J Natl Cancer Inst 1978;61:639-643.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
13. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-174.
14. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21:505-515.
15. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-752.
16. Folberg R, Hendrix MJC, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156:361-381.
17. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. Prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993;100:1389-1398.
18. Makitie T, Summanen P, Tarkkanen A, Kivela T. Microvascular loops and neworks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 1999;91:359-367.
19. Sakamoto T, Sakamoto M, Yoshikawa H, et al. Histologic findings and prognosis of uveal malignant melanoma in Japanese patients. Am J Ophthalmol 1996;121:276-283.
20. Seregard S, Spangberg B, Juul C, Oskarsson M. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology 1998; 105:485-491.
21. Thies A, Mangold U, Moll I, Schumacher U. PAS-positive loops and networks as a prognostic indicator in cutaneous malignant melanoma. J Pathol 2001;195:537-542.
22. Warso MA, Maniotis AJ, Chen X, et al. Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 2001;7:473-477.
23. Rummelt V, Mehaffey MG, Campbell RF, et al. Microcirculation architecture of metastases from primary ciliary body and choroidal melanomas. Am J Ophthalmol 1998;126:303-305.
24. Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogen-esis of inflammatory breast cancer xenograft. Cancer Res 2002;62:560-566.
25. Garber K. Angiogenesis inhibitors suffer new setback. Nat Biotech 2002;20:1067-1068.
26. van der Schaft DWJ, Seftor, EA, Hess AR, et al. The differential effects of angiogenesis inhibitors on vascular network formation by endothelial cells versus aggressive melanoma tumor cells. Proc AACR 2003;44:696.
27. McDonald DM, Munn L, Jain RK. Vasculogenic mimicry: how convincing, how novel, and how significant? Am J Pathol 2000;156:383-388.
28. Hess AR, Seftor EA, Gardner LMG, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001;61: 3250-3255.
29. Tachibana M, Takeda K, Nobukuni Y, et al. Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocytes characteristics. Nat Genet 1996; 14:50-54.
30. Hendrix MJC, Seftor EA, Meltzer PS, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001;98:8018-8023.
31. Seftor REB, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 y2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001;61:6322-6327.
32. Hynes RO, Bader BL, Hodivala-Diik K. Integrins in vascular development. Braz J Med Biol Res 1999;32:501-510.
33. Hynes RO. Specificity of cell adhesion in development: the cadherin superfamily. Curr Opin Genet Dev 1992;2:621-624.
34. Kemler R. Classical cadherins. Semin Cell Biol 1992;3:149-155.
35. Lampugnani MG. A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J Cell Biol 1992;118:1511-1522.
36. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;4:345-357.
37. Pasquale EB. The Eph family of receptors. Curr Opin Cell Biol 1997;9:608-615.
38. Rosenburg IM, Goke M, Kana, M, Reinecker HC, Podolsky DK. Epithelial cell kinase-B-61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 1997; 273(4 part 1):G824-G832.
39. Straume O, Akslen LA. Importance of vascular phenotype by basic fibrolast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and Ephrin-A1/EphA2 on melanoma progression. Am J Pathol 2001;160:1009-1019.
40. Easty DJ, Hill SP, Hsu MY, et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999;84:494-501.
41. Malinda KM, Kleinman HK. The laminins. Int J Biochem Cell Biol 1996;28:957-995.
42. Colognato H, Yurchenco PD. Form and function: the laminin family of heterotrimers. Dev Dynamics 2000;218:213-234.
43. Malinda KM, Nomizu M, Chung M, et al. Identification of laminin a1 and (31 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J 1999;13:53-62.
44. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000;148:615-624.
45. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-228.
46. Seftor REB, Seftor EA, Kirschmann DA, Hendrix MJC. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 y2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Therapeut 2002;1:1173-1179.
47. Korpelainen EI, Alitalo K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 1998;10:159-164.
48. Yancopoulos DG, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
49. Hess AR, Seftor EA, Seftor REB, Hendrix MJC. Phosphoinositide 3-kinase acts downstream of EphA2 to regulate the membrane-type 1 matrix metalloproteinase (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) promoting vasculogenic mimicry in vitro. Mol Biol Cell 2002; 13:210A.
50. Hess AR. Molecular dissection of melanoma tumor cell vasculogenic mimicry. Doctoral Dissertation, The University of Iowa: 2002.
51. Shubik P, Warren BA. Additional literature on "vasculogenic mimicry" not cited. Am J Pathol 2000;156:736.
52. Warren BA, Shubik P. The growth of the blood supply to melanoma transplants in the hamster cheek pouch. Lab Invest 1966;15:464-478.
53. Tímár J, Tóth J. Tumor sinuses-vascular channels. Pathol Oncol Res 2000;6(2):83-86.
54. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-1380.
55. Mueller AJ, Maniotis AJ, Freeman WR, et al. An orthotopic model for human uveal melanoma in SCID mice. Microvasc Res 2002;64:207-213.
56. Clarijs R, Otte-Holler I, Ruiter DJ, de Waal RMW. Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci 2002; 43:912-918.
57. Maniotis AJ, Chen X, Garcia C, et al. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab Invest 2002;82:1031-1043.
58. Potgens AJG, van Altena MC, Lubsen NH, Ruiter DJ, de Waal RMW. Analysis of the tumor vascu-lature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. Am J Pathol 1996;148:1203-1217.
59. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000;97: 14, 608-14, 613.
60. Döme B, Paku S, Somlai B, Tímár J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J Pathol 2002;197:355-362.
61. Hendrix MJC, Seftor EA, Meltzer PS, et al. The plasticity of aggressive melanoma tumor cells: recapitulation of an embryonic stem cell program. Rec Adv Res Updates 2002;3:191-200.
62. Ruf W, Seftor EA, Petrovan R, et al. Differential role of tissue factor pathway inhibitor-1 and 2 (TFPI-1 and 2) in melanoma vasculogenic mimicry. Cancer Res 2003;63:5381-5389.
63. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nat Med 2002;8:841-849.
64. Clarijs R, Schalkwijk L, Ruiter DJ, de Waal RMW. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:1422-1428.
65. Witte MH, Bernas MJ, Martin CP, Witte CL. Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. Microscopy Res Tech 2001;55:122-145.
66. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002;1:219-227.
67. Padera TP, Kadambi A, Di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-1886.
68. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 2002;8:751-755.
69. Hendrix MJC, Seftor REB, Seftor EA, et al. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res 2002;62:665-668.
70. Uyttendaele H, Ho J, Rossant J, Kitajewski J. Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci USA 2001;98:5643-5648.
71. Gridley T. Notch signaling during vascular development. Proc Natl Acad Sci USA 2001;98: 10, 733-10, 738.
72. Qin J-Z, Chaturvedi V, Hendrix MJC, et al. Interrupting activated Notch signaling triggers apoptosis in melanoma cells. Soc Intern Invest Derm 2003;0185.
73. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649-661.
74. Robbins J, Blonel BJ, Gallahan D, Callahan R. Mouse mammary tumor gene Int-3: a member of the Notch gene family transforms mammary epithelial cells. J Virol 1992;66:2594-2599.
75. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci USA 1995;92:6414-6418.
76. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao W-Q. Dynamics of Notch expression during murine prostate development and tumorigenesis. Cancer Res 2001;61:7291-7297.
77. Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic pheno-type in human Ras-transformed cells. Nature Med 2002;8:979-986.
78. Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Therapy 2002;1:466-476.
79. Klausner RD. The fabric of cancer cell biology-weaving together the strands. Cancer Cell 2002;1:3-10.
80. Kim CJ, Reintgen DS, Yeatman TJ. The promise of microarray technology in melanoma care. Cancer Control 2002;9:49-53.
81. Chen X, Maniotis AJ, Majumdar D, Pe'er J, Folberg R. Uveal melanoma cells staining for CD34 and assessment of tumor vascularity. Invest Ophthalmol Vis Sci 2002;43:2533-2539.
82. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
83. Anderson DJ, Gage FH, Weissman L. Can stem cells cross lineage boundaries? Nature Med 2001;7:393-395.
84. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000;100:157-168.
85. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002;298:601-604.
86. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 2002;298:597-600.
87. Stocum DL. A tail of transdifferentiation. Science 2002;298:1901-1903.
88. LaBarge MA, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 2002;111:589-601.
89. Kon K, Fujiwara T. Transformation of fibroblasts into endothelial cells during angiogenesis. Cell Tissue Res 1994;278:625-628.
90. Condorelli G, Borello U, De Angelis L, et al. Cardiomyocytes induce endothelial cells to transdifferentiate into cardiac muscle: implications for myocardium regeneration. Proc Natl Acad Sci USA 2001;98:10, 733-10, 738.
91. Nickoloff BJ, Foreman KE. Etiology and pathogenesis of Kaposi's sarcoma. Recent Results Cancer Res 2002;160:332-342.
92. Bissell MJ, Radisky D. Putting tumors in context. Nat Rev Cancer 2001;1:46-54.
93. Liao F, Li Y, O'Connor W, et al. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res 2000;60:6805-6810.
94. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 2002;8:563-571.
95. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
96. O'Reilly MS. Vessel maneuvers: vaccine targets tumor vasculature. Nat Med 2002;8:1352-1354.
97. Miller KD, Sweeney CJ, Sledge GW Jr. The snark is a boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol 2003;14:20-28.
98. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-3927.
99. Gee MS, Procopio WM, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on th effectiveness of anti-vascular therapy. Am J Pathol 2003;162:183-193.
100. Goetz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 2002;62:6371-6375.
101. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-2407.
102. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metast Rev 2001;20:3-11.
103. Eberhard A, Kahlert S, Goede V, Hemerlein B, Plate KH, Augustin HG. Heterogeneity of angiogen-esis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-1393.
104. Ryback SM, Sanovich E, Hollingshead MG, et al. "Vasocrine" formation of tumor cell-lined vascular spaces: implications for rationale design of antiangiogenic therapies. Cancer Res 2003;63: 2812-2819.
105. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-2392.
106. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
107. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001;411:375-379.